AdvanCell is developing the investigational medicinal product [212Pb]Pb-ADVC001 (212Pb-ADVC001 hereafter for simplicity), a PSMA-targeting ligand radiolabeled with 212Pb intended for the treatment of patients with prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.